Latest Period
Q4 2025
Security Snapshot
Revolution Medicines, Inc. - Common Stock (RVMD) Institutional Ownership
CUSIP: 76155X100
13F Institutional Holders and Ownership History from Q1 2020 to Q1 2026
Institutions Reporting
385
Shares (Excl. Options)
199,291,356
Price
$79.65
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- RVMD on Nasdaq
- Shares outstanding
- 192,966,469
- Price per share
- $98.64
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 199,291,356
- Total reported value
- $15,874,866,294
- % of total 13F portfolios
- 0.03%
- Share change
- +5,666,804
- Value change
- +$489,477,380
- Number of holders
- 385
- Price from insider filings
- $98.64
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- RVMD - Revolution Medicines, Inc. - Common Stock is tracked under CUSIP 76155X100.
- 385 institutions reported positions in Q4 2025.
- 6 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 385 to 271 between Q4 2025 and Q1 2026.
- Reported value moved from $15,874,866,294 to $5,306,500,345.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 385 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 76155X100?
CUSIP 76155X100 identifies RVMD - Revolution Medicines, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 76155X100:
Significant Owners of Revolution Medicines, Inc. - Common Stock (RVMD) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Farallon Capital Partners, L.P. | 7.5% | -5% | $1,499,170,464 | +$137,025,822 | 14,596,149 | +10% | Dapice Joshua J. | 31 Dec 2025 |
| JANUS HENDERSON GROUP PLC | 6.1% | +6.7% | $530,327,722 | +$35,740,771 | 11,356,054 | +7.2% | JANUS HENDERSON GROUP PLC | 30 Sep 2025 |
| BAKER BROS. ADVISORS LP | 4.9% | -2% | $971,159,717 | +$9,283,443 | 9,455,357 | +0.97% | Baker Bros. Advisors LP | 31 Dec 2025 |
| FMR LLC | 5% | $439,058,769 | 9,401,687 | FMR LLC | 30 Sep 2025 | |||
| BlackRock, Inc. | 4.5% | $309,009,603 | 8,399,214 | BlackRock, Inc. | 30 Jun 2025 | |||
| WELLINGTON MANAGEMENT GROUP LLP | 3.6% | -32% | $717,700,402 | -$336,077,288 | 6,987,639 | -32% | Wellington Management Group LLP | 31 Dec 2025 |
As of 31 Dec 2025, 385 institutional investors reported holding 199,291,356 shares of Revolution Medicines, Inc. - Common Stock (RVMD). This represents 103% of the company’s total 192,966,469 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Revolution Medicines, Inc. - Common Stock (RVMD) together control 73% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| VANGUARD GROUP INC | 8.7% | 16,719,886 | +6.7% | 0.02% | $1,331,738,920 |
| FARALLON CAPITAL MANAGEMENT LLC | 7.6% | 14,582,796 | -0.29% | 6.7% | $1,161,519,701 |
| JANUS HENDERSON GROUP PLC | 6.4% | 12,303,502 | +8.3% | 0.44% | $980,035,989 |
| BAKER BROS. ADVISORS LP | 4.9% | 9,455,357 | 0% | 4.4% | $753,119,185 |
| BlackRock, Inc. | 4.6% | 8,926,656 | +7.2% | 0.01% | $711,008,150 |
| FMR LLC | 4.5% | 8,587,981 | -8.7% | 0.03% | $684,032,699 |
| Nextech Invest, Ltd. | 3.9% | 7,601,087 | 0% | 59% | $605,426,580 |
| WELLINGTON MANAGEMENT GROUP LLP | 3.6% | 6,987,639 | -29% | 0.1% | $556,565,446 |
| Paradigm Biocapital Advisors LP | 3.4% | 6,644,403 | +6.8% | 14% | $529,226,699 |
| Bellevue Group AG | 2.6% | 5,005,719 | -10% | 7.6% | $398,705,518 |
| STATE STREET CORP | 2.1% | 4,109,290 | -22% | 0.01% | $327,304,949 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.8% | 3,404,717 | -12% | 0.03% | $271,186,000 |
| BVF INC/IL | 1.7% | 3,356,782 | -16% | 9% | $267,367,686 |
| Alphabet Inc. | 1.7% | 3,345,102 | -19% | 10% | $266,437,374 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.6% | 3,161,963 | +0.52% | 0.02% | $251,911,578 |
| UBS Group AG | 1.6% | 3,087,937 | +184% | 0.05% | $245,954,181 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 1.5% | 2,894,613 | -21% | 3% | $230,555,925 |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 1.5% | 2,845,013 | +13% | 0.94% | $226,605,319 |
| GENERAL ATLANTIC, L.P. | 1.5% | 2,812,928 | +14% | 7.8% | $224,049,715 |
| Casdin Capital, LLC | 1.3% | 2,577,333 | -2.6% | 13% | $205,284,573 |
| Woodline Partners LP | 1.3% | 2,500,895 | -14% | 0.77% | $199,196,287 |
| GOLDMAN SACHS GROUP INC | 1.3% | 2,491,583 | +238% | 0.03% | $198,454,586 |
| NORGES BANK | 1.3% | 2,455,347 | 0.02% | $195,568,389 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.1% | 2,205,555 | +197% | 0.27% | $175,672,456 |
| T. Rowe Price Investment Management, Inc. | 1.1% | 2,200,376 | -54% | 0.11% | $175,260,000 |
Institutional Holders of Revolution Medicines, Inc. - Common Stock (RVMD) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 54,598,508 | $5,306,500,345 | -$194,949,102 | $97.25 | 271 |
| 2025 Q4 | 199,291,356 | $15,874,866,294 | +$489,477,380 | $79.65 | 385 |
| 2025 Q3 | 191,767,706 | $8,955,119,353 | +$87,454,891 | $46.70 | 318 |
| 2025 Q2 | 190,726,235 | $7,017,009,498 | -$4,134,347 | $36.79 | 305 |
| 2025 Q1 | 191,051,347 | $6,776,444,446 | -$111,943,197 | $35.36 | 281 |
| 2024 Q4 | 193,048,484 | $8,445,124,761 | +$672,301,180 | $43.74 | 278 |
| 2024 Q3 | 170,577,261 | $7,735,337,873 | +$69,484,732 | $45.35 | 252 |
| 2024 Q2 | 168,410,110 | $6,536,274,916 | +$309,463,084 | $38.81 | 221 |
| 2024 Q1 | 160,549,965 | $5,174,502,235 | +$41,971,613 | $32.23 | 207 |
| 2023 Q4 | 159,991,814 | $4,588,662,174 | +$1,173,667,984 | $28.68 | 183 |
| 2023 Q3 | 112,410,338 | $3,111,480,815 | +$13,449,543 | $27.68 | 165 |
| 2023 Q2 | 111,960,439 | $2,994,417,481 | +$107,072,959 | $26.75 | 138 |
| 2023 Q1 | 108,245,336 | $2,343,498,970 | +$420,665,649 | $21.66 | 149 |
| 2022 Q4 | 88,251,337 | $2,102,174,977 | +$32,658,345 | $23.82 | 133 |
| 2022 Q3 | 88,392,782 | $1,743,047,001 | +$233,806,685 | $19.72 | 133 |
| 2022 Q2 | 76,461,750 | $1,490,187,152 | +$40,971,035 | $19.49 | 125 |
| 2022 Q1 | 73,955,592 | $1,885,584,241 | +$15,751,102 | $25.51 | 122 |
| 2021 Q4 | 73,332,089 | $1,845,795,329 | -$50,104,402 | $25.17 | 113 |
| 2021 Q3 | 68,952,735 | $1,896,915,710 | +$49,809,012 | $27.51 | 109 |
| 2021 Q2 | 70,364,140 | $2,233,248,707 | +$91,598,352 | $31.74 | 127 |
| 2021 Q1 | 66,456,882 | $3,048,913,145 | +$424,322,383 | $45.88 | 124 |
| 2020 Q4 | 57,426,011 | $2,273,517,142 | +$133,648,027 | $39.59 | 118 |
| 2020 Q3 | 56,953,834 | $1,981,075,717 | +$339,721,674 | $34.80 | 90 |
| 2020 Q2 | 46,886,789 | $1,478,128,925 | +$22,763,370 | $31.57 | 73 |
| 2020 Q1 | 46,881,176 | $1,025,119,285 | +$1,024,845,284 | $21.91 | 72 |